N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=88 Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
Hemorrhage
Primary: CBC Hemoglobin Measurement Compared to Non-invasive Radical-7 Measurement — 10.7; 9.2 grams per deciliter
N/A N=15 Presence or Absence of Blood in the GI Lumen
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
Phase 4 N=437 Fibrinogen in Haemorrhage of Delivery
Post-Partum Hemorrhage
Primary: Failure Rate of PPH Management — 75; 80; 92; 92 Participants — p=0.9563
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
N/A N=101 EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants
N/A N=258 HEMOBLAST Pivotal Clinical Investigation
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis — 148; 61 Participants — p=<0.0001
N/A N=106 Accuracy of Blood Loss Estimation After Vaginal Delivery
Postpartum Hemorrhage
Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=113 Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
Peripheral Arterial Hemorrhage
Primary: Percentage of Participants With Composite of Freedom From Major Adverse Events (MAEs) — 100 percentage of participants — p=<0.025
Phase 1 N=27 HEMOBLAST Pilot Clinical Investigation
Hemostasis
Primary: Mean Paired Kappa Statistic for the Assignment of SBSS Scores by 2 Investigators — 0.7754 Kappa statistic
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Phase 1 N=7 Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
N/A N=15 A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding Score — 2.33; 0.13 score on a scale — p=<.0001
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
Phase 2 N=33 A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery
Hemostasis · General Surgery
Primary: To Evaluate the Safety of sFilm-FS Versus an Active-comparator (TACHOSIL®) When Used as Adjunct to Conventional Hemostatic Techniques During Elective Surgery Through…
Phase 2 N=44 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine
Healthy
Primary: Tolerance to Simulated Hemorrhage — 385; 692 CSI: Cumulative Stress Index
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
N/A N=62 Phlebotomy to Prevent Blood Loss in Major Hepatic Resections
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
N/A N=50 Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis
Hemorrhage · Pelvic Fracture
Primary: Mortality Rate — 0; 1 Participants
Phase 2 N=20 Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Measurement of Epistaxis in Patients With HHT as Measured by the HHT Foundation Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Ferritin Levels.
N/A N=35 The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty
Anesthesia
Primary: The Hemoglobin (in g/dl) Levels — 12.2; 12.0; 11.9; 11.8 g/dl
Phase 2 N=10 Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Epistaxis Using the Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Feritin Levels..
N/A N=300 War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)
Hemorrhoids · Hemorrhoidal Disease
Primary: Hemorrhoid Regression Rate — 117; 33 Participants — p=<0.001
N/A N=236 Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting
Hemostasis · Bleeding
Primary: The Time to Hemostasis Measured From Start of Study Treatment to the Achievement of Hemostasis at the Target Bleeding Site (TBS), or to the End of the 10-minute…
Phase 3 N=523 PreHospital Air Medical Plasma Trial
Hemmorhagic Shock During Air Medical Transport
Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants
N/A N=50 Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery
Liver Disease
Primary: Median Time to Achieve Hemostasis Following Application of Study Treatment. — 1; 3 Minutes — p=<0.0001